Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5508887 · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| RO5508887 | EXPERIMENTAL | - |
| Part 1a | EXPERIMENTAL | - |
| Part 1b | PLACEBO_COMPARATOR | - |
| Part 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Multiple doses of placebo |
| RO5508887 | DRUG | Multiple doses of RO5508887 |
Inclusion Criteria: * Adult healthy volunteers, \>/=18 years of age * Body mass index (BMI) between 18 and 30 kg/m2 inclusive * Use of adequate contraception methods or surgically sterile Exclusion Criteria: * Evidence of active or chronic disease * Regular consumption of drugs of abuse * Regular...
RO5508887 is an investigational small molecule being studied in healthy volunteers. It has been evaluated in Phase 1 clinical trials to assess its safety, pharmacokinetics, and pharmacodynamics. The drug is not approved for any condition and remains in clinical development.
RO5508887 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company has sponsored multiple Phase 1 trials of this investigational small molecule in healthy volunteers.
RO5508887 is in Phase 1 clinical development. All three completed trials of the drug were Phase 1 studies conducted in healthy volunteers. The drug is investigational and has not been approved by regulatory authorities.
RO5508887 has been studied in three completed Phase 1 trials: NCT01461967, NCT01592331, and NCT01664143. These trials enrolled a total of 127 healthy volunteers and were conducted in France and the United States.
RO5508887 is the only name provided for this investigational drug. No alternative names have been identified in the available information. It is a small molecule being developed by Roche Holding AG.
The mechanism of action of RO5508887 has not been disclosed in the available information. It is a small molecule being studied in healthy volunteers for its safety, pharmacokinetics, and pharmacodynamics in Phase 1 trials.